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Introduction: Although dermatomyositis (DM) and polymyositis (PM) share many clinical 
features in common, they have distinct pathophysiological and histological features. It is 
possible that these distinctions reflect also macroscopically, for example, in muscle altera-
tions seen in magnetic resonance images (MRI). 
Objectives: To compare simultaneously the MRI of various muscle compartments of the 
thighs of adult DM and PM. 
Materials: The present study is a cross-sectional that included, between 2010 and 2013, 11 
newly diagnosed DM and 11 PM patients (Bohan and Peter’s criteria, 1975), with clinical and 
laboratory activity. They were valued at RM thighs, T1 and T2 with fat suppression, 1.5 T MRI 
scanner sequences. 
Results: The mean age at the time of MRI, the time between onset of symptoms and the 
realization of the MRI distribution of sex and drug therapy were comparable between the 
two groups (p>0.050). Concerning the MRI, muscle edema was significantly found in DM, 
and mainly in the proximal region of the muscles. The area of fat replacement was found 
predominantly in PM. The partial fat replacement area occurred mainly in the medial and 
distal region, whereas the total fat replacement area occurred mainly in the distal muscles. 
There was no area of muscle fibrosis. 
Conclusions: DM and PM have different characteristics on MRI muscles, alike pathophysiolo-
gical and histological distinctions.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Aspectos distintos de ressonância magnética de músculos entre 
dermatomiosite e polimiosite
Palavras-chave:
Dermatomiosite
Doença muscular
Polimiosite
Ressonância magnética
r e s u m o
Introdução: Embora a dermatomiosite (DM) e a polimiosite (PM) compartilhem diversos as-
pectos clínicos em comum, cada uma delas apresenta características fisiopatológicas e his-
tológicas próprias. É possível que estas diferenças também se reflitam macroscopicamente, 
como, por exemplo, em imagens musculares vistas em ressonância magnética (RM). 
Objetivos: Comparar simultaneamente a RM de diversos compartimentos musculares das 
coxas de pacientes com DM e PM adultos.
Materiais: Estudo transversal, em que foram avaliadas, entre o período de 2010 a 2013, as 
imagens de RM das coxas realizadas em aparelho de 1,5 Tesla (T) com sequências pon-
deradas em T1 e T2 com supressão de gordura, para rastreamento, de 11 DM e 11 PM (Bohan 
e Peter, 1975) recém-diagnosticados, em atividade clínica e laboratorial. 
Resultados: A média de idade na ocasião da RM, o tempo entre o início de sintomas e a 
realização das RM, a distribuição de sexos e a terapia medicamentosa foram comparáveis 
entre os dois grupos (p>0,050). Em termos de RM, edema muscular foi encontrado signifi-
cantemente em DM, e principalmente na região proximal dos músculos. A área de lipossub-
stituição dos músculos foi encontrada predominantemente em PM. Essa lipossubstituição, 
quando de uma forma parcial, ocorreu principalmente nos terços médio e distal, enquanto 
que a forma total transcorreu apenas no terço distal dos músculos. Não houve nenhuma 
área de fibrose muscular. 
Conclusões: A DM e a PM apresentam características distintas entre si em RM de músculos, 
a exemplo de distinções fisiopatológicas e histológicas.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Dermatomyositis (DM) and polymyositis (PM) are part of a 
group of systemic autoimmune diseases characterized by 
symmetric and progressive proximal muscle weakness of 
limbs. Moreover, extramuscular manifestations (i.e. articular, 
heart, lung and gastrointestinal tract involvement) may oc-
cur.1,2 In the case of DM, typical skin changes still occur, such 
as heliotrope and/or Gottron’s papules.
Although DM and PM share many similar clinical and labo-
ratory features, each of these conditions also exhibit distinct 
epidemiological, pathophysiological and histological charac-
teristics. Thus, from the histological and physiopathological 
standpoint, in PM there is a focal infiltrate of CD8 (+) lympho-
cytes and macrophages in the muscle fibers, which, in turn, 
express high levels of MHC class I antigens and release per-
forin granules,3 resulting in lysis and necrosis of the muscle 
fibers themselves,4 as well as fat in replacement areas and 
tissue fibrosis. In the case of DM, there are several features 
that suggest an important role of B cells in the pathogenesis 
of the disease, such as the presence of autoantibodies, im-
mune complex deposition in the dermo-epidermal junction 
in skin lesions, the presence of B cells in sore muscles,5,6 and 
in perivascular areas.7,8 In addition to this, the deposition of 
complement and immunoglobulin in the perifascicular endo-
thelium can lead to muscle ischemia and atrophy, showing 
the importance of humoral immunity.9
It is plausible that these differences observed between DM 
and PM are also macroscopically reflected, such as in muscle 
images obtained from studies of magnetic resonance imaging 
(MRI), although to date there are no studies in the literature 
demonstrating these possible differences.
MRI has been used in idiopathic inflammatory myopathies 
as an additional instrument to assess disease activity, thera-
peutic monitoring, and prognosis of disease, as well as a guide 
to the most likely location to find positive areas of inflamma-
tory infiltrate in a muscle biopsy.10-23 However, most of these 
studies are based on juvenile DM.10,11,13,14,17,18,22 On the other 
hand, there is paucity of MRI studies on adult DM patients, as 
well as on PM ones,12,16,23 and this served as motivation for us 
to conduct this study.
Patients and methods
This was a cross-sectional study that, during the period from 
2010 to 2013, assessed 11 DM patients and 11 PM patients 
defined by Bohan and Peter criteria and recently diagnosed 
as with clinical and laboratory activity.24,25 Patients with a di-
agnosis of amyopathic DM, myopathies associated with ma-
lignancy or other types of collagenosis were not included, as 
well as patients under the age of 18 years. 
The present work is a sequel of a study previously ap-
proved by the local Ethics Committee [HC 0039/10].
Originally, all patients had been hospitalized in our de-
partment for a clinical research of progressive proximal 
muscle weakness in their limbs, and also because of an in-
crease in serum levels of muscle enzymes without an ap-
parent cause. According to our service protocol, possible 
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differential diagnoses were dismissed; and, prior to muscle 
biopsy for diagnostic purposes, the patients underwent a 
MRI of the muscles of the thighs. Searching a database of 
previously standardized electronic data (electronic medical 
record), the following data were collected: current age; eth-
nicity; gender; time between onset of symptoms and MRI; 
limb muscle strength (grade 0: absence of muscle contrac-
tion; grade I: signs of slight contractility; grade II: normal 
range of motion, but without overcome the action of grav-
ity; grade III: normal range of motion against gravity; grade 
IV: full mobility against gravity, with a certain degree of re-
sistance; and grade V: complete mobility against strong re-
sistance and against gravity);26 serum levels of muscle en-
zymes [creatine phosphokinase (normal range: 24-173 U/L) 
and aldolase (normal range: 1.0-7.5 U/L) determined by an 
automated kinetic method]; autoantibodies against cellular 
components, determined by indirect immunofluorescence, 
using Hep-2 cells as substrate; pre-MRI medicamentous his-
tory (corticosteroids and/or immunosuppressants). 
MRI was performed by fast spin echo technique, obtain-
ing T1- and T2-weighted sequences with fat suppression, in 
multiplanar acquisitions, using a Philips 1.5 T unit from the 
Department of Radiology at our institution. Fifteen muscles 
were evaluated: sartorius, vastus lateralis, vastus interme-
dius, vastus medialis, rectus femoris, tensor fasciae latae, 
adductor longus, adductor brevis, adductor magnus, pectin-
eus, gracilis, gluteus maximus, semitendinosus, semimem-
branosus and biceps femoris. The following parameters were 
evaluated for each muscle in its proximal, middle and distal 
thirds: presence or absence of an edema area, fibrosis, and 
fat replacement (partial or total). Furthermore, we evaluated 
the overall appearance of muscles, as being normal or hypo/
atrophic. The images were evaluated by two radiologists with 
proven experience in muscle MRI analysis. These profession-
als worked independently and were unaware of the clinical 
cases.
Statistical analysis
Our data were expressed as mean ± standard deviation (SD), 
median (interquartils) or percentage (%), being assessed for 
normal distribution by Kolmogorov-Smirnov analysis. The 
Student t test and Mann-Whitney test were used for the anal-
ysis of continuous data. The Fisher exact test was used to ana-
lyze categorical data. These calculations were performed with 
the computer program STATA version 7.0 (STATA, College Sta-
tion, TX, USA). P-values <0.050 were considered statistically 
significant.
Results
The means of age at the time of MRI, gender distribution, 
and ethnicity, as well as the time interval between the onset 
of symptoms and MRI examination of thighs, were compa-
rable between DM and PM patients (p>0.050), as shown in 
Table 1. The intensities of muscle weakness and levels of 
muscle enzymes were also similar in both groups (p>0.050). 
In terms of drug therapy, 100.0% of DM patients and 81.8% of 
PM patients were already on corticosteroids and/or immu-
nosuppressants – eight patients with azathioprine (2-3 mg/
kg/day), four with methotrexate (15-25 mg/week), one with 
cyclosporine (3 mg/kg/day), one with leflunomide (20 mg/
day) and/or three with intravenous human immunoglobulin 
(2 g/kg/day), at the time of the clinical picture investigation 
and of MRI. Nevertheless, the cumulative dose of prednisone 
and the previous use of immunosuppressive drugs and of 
pulse therapy with methylprednisolone were similar in both 
groups (p>0.050).
In MRI, a significant muscle edema was found in DM pa-
tients (41.7 to 91.7% of muscle compartments) compared with 
PM patients (from 8.3% to 33.3% of the muscle compartments) 
(p<0.050). Moreover, in 50% of the examined muscles in DM 
patients, the edema decreases in the proximal-distal direc-
tion, as shown in Fig. 1.
The area of fat replacement of muscles was predominantly 
observed in different muscle compartments in PM patients, 
when compared to DM patients. When partial, this fat re-
placement affected mainly the middle and distal thirds of the 
muscles of PM patients (0% to 41.7% of the muscles; Fig. 2), 
while a total fat replacement was observed only in the distal 
third of muscles of PM patients (0% to 16.7% of the muscles; 
Fig. 3). 
Table 1 – Demographic, clinical, laboratory and drug 
therapy characteristics of patients with dermatomyositis 
and polymyositis
Characteristics DM (n=11) PM (n=11) p
Age (years) 50.9±11.4 49.9±16.2 0.868
Female gender 9 (81.8) 10 (90.9) 1.000
Caucasian 9 (81.8) 8 (72.7) 1.000
Time: MRI – symptoms 
(months)
16.7±22.2 29.0±20.3 0.191
Muscle strength
Upper limbs
Grade V 1 (9.1) 5 (45.5) 0.155
Grade IV 5 (45.5) 4 (36.4) 1.000
Grade III 4 (36.4) 2 (18.2) 0.635
Grade II 1 (9.1) 0 1.000
Lower limbs
Grade V 0 1 (9.1) 1.000
Grade IV 5 (45.5) 7 (63.6) 0.670
Grade III 5 (45.5) 2 (18.2) 0.361
Grade II 1 (9.1) 1 (9.1) 1.000
Muscle enzymes
Creatine 
phosphokinase (U/L)
1340 (158-3489) 870 (207-2519) 0.768
Aldolase (U/L) 11.2 (7.4-29.0) 9.7 (6.6-20.6) 0.577
Antinuclear factor 7 (63.6) 5 (45.5) 0.670
Methylprednisolone 
(pulse therapy)
3 (27.3) 2 (18.2) 1.000
Prednisone 11 (100.0) 9 (81.8) 0.476
Cumulative dosage 
(mg), <1 m
1200 (180-2100) 300 (300-1500) 0.290
Cumulative dosage 
(g), <3 m
3.0±3.2 1.4±1.1 0.190
Immunosuppressants 3 (27.3) 6 (54.5) 0.387
Data are expressed as mean ± standard deviation, median 
(interquartils), or percentage (%). 
DM, dermatomyositis; PM, polymyositis; MRI, magnetic resonance 
imaging. 
Immunosuppressants, azathioprine (2-3 mg/kg/day), methotrexate 
(15-25 mg/week)
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In the present study, no area of muscle fi brosis was identi-
fi ed.
Discussion
The present study showed that DM and PM, although sharing 
many clinical and laboratory aspects in common, have differ-
ent characteristics from the point of view of muscle MRI. 
Of the few studies that addressed the use of MRI in idio-
pathic infl ammatory myopathies,10-23 most are restricted to ju-
venile DM.10,11,13,14,17,18,22 In the case of PM and DM in adults,12,16,23 
the studies available in the literature are scarce.
Kaufman et al.23 globally analyzed fi ve PM patients and 
eight DM patients with a broad age range (12-77 years). The 
authors made no mention of the disease duration or type of 
drug therapy received by their patients prior to MRI,23 and 
compared the MRI fi ndings according to disease activity. We 
chose to evaluate and compare concomitantly adult DM and 
PM patients in various muscle compartments of their thighs 
at an early stage of the disease. Furthermore, our patients 
had similar demographic, clinical, laboratory, and therapeutic 
characteristics to each other, allowing a meaningful compari-
son of MRI fi ndings.
Tomasová et al.16 evaluated nine PM patients and 20 DM 
patients, with a mean duration of disease of 2.3 years. All pa-
tients exhibited clinically and biochemically active disease, 
and 63.2% of these cases had never received drug therapy. 
These authors showed a correlation between the intensity of 
muscle edema observed by MRI with the degree of disease ac-
tivity and the positivity for an infl ammatory infi ltrate found 
in muscle biopsies guided by MRI.16 However, these authors 
did not make comparisons regarding possible changes on MRI 
in PM and DM.
Reimers et al.12 evaluated MRI studies of various muscle 
compartments of lower limbs of 58 patients aged 21-83 years-
old. However, in addition to the 14 DM patients and 25 PM 
patients, eight patients with granulomatous myositis and 11 
patients with inclusion body myositis were included. More-
over, Reimers et al. did not mention the type of drug treat-
ment received by the participants in the study, who were 
arbitrarily classifi ed as acute (less than one year disease), or 
chronic (when there is signifi cant evidence of fat replacement 
and of muscle fi brosis in muscle MRI) patients. Despite these 
limitations, the authors observed that the presence of areas of 
muscle edema and of fat replacement were respectively more 
and less frequent in patients with acute DM, when compared 
to the other diseases included in the analysis.
Our results showed that the area of muscle edema was 
present mainly in DM patients, when compared with PM 
patients. This may be a result of the previous use of cortico-
steroids, which may infl uence the intensity and presence of 
muscle edema.16 However, we observed that both the use of 
corticosteroids (cumulative dose) and immunosuppressants 
Fig. 3 – Distribution of total fat replacement area of different 
muscle compartments of the thigh by MRI in patients with 
dermatomyositis and polymyositis
Fig. 1 – Distribution of edema area in different muscle 
compartments of the thigh by MRI in patients with 
dermatomyositis and polymyositis
Fig. 2 – Distribution of partial fat replacement area of 
different muscle compartments of the thigh by MRI in 
patients with dermatomyositis and polymyositis
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were similar in both DM and PM groups of patients. Moreover, 
other parameters – such as the time of drug treatment, and 
the time between the MRI and the onset of muscle weakness 
symptoms were similar in both groups, which shows that the 
presence of muscle edema was an inherent characteristic of 
patients with active and newly diagnosed DM.
In addition, the fact that the swelling is mainly located on 
the proximal thigh, compared to the distal region, is compat-
ible with the clinical findings, in those there is objective evi-
dence of increased muscle weakness in so far as we get closer 
to the waists.
The prevalence of presence of fat replacement areas was 
low in our study, probably because we evaluated only cases of 
newly diagnosed DM and PM. Partially impaired muscle areas 
(partial fat replacement) were present in most muscle com-
partments, especially in PM. On the other hand, significantly 
compromised areas (total fat replacement) were only present 
in the muscles of PM patients, mainly in the long muscles, in 
the distal area, and in the posterior muscle group of thighs. 
These findings can be explained by the fact that these mus-
cles are subjected to less traction and mechanical stimulation 
during the ambulation.
Previous studies have shown the benefit of physical ex-
ercise in patients with idiopathic inflammatory myopathies. 
Resistance exercises, for example, can reduce the expression 
of genes involved in the inflammatory process and fibrosis in 
the muscle tissue.27 
In the present study, no areas of muscle fibrosis were ob-
served, both in DM as in PM patients. In general, the presence 
of areas of muscle fibrosis, as well as those of fat replacement, 
are commonly observed in patients with a diagnosis of chron-
ic myositis unresponsive to medical therapy.28
Our study has its limitations: it has a cross-sectional 
design, and therefore the correlation between muscle MRI 
findings and clinical and laboratory manifestations of pa-
tients were not evaluated. Second, ours was a small sample. 
Third, we evaluated only the muscle groups of the thighs 
and therefore did not have enough substrate to generalize 
this difference in muscle MRI findings to other muscle com-
partments of DM and PM patients. Fourth, no correlation be-
tween the muscle MRI data with possible findings of muscle 
biopsy was performed. And last but not least, not all patients 
were naïf as to drug therapy at the time of MRI, which may 
under or overestimate the muscle MRI findings of the pa-
tients analyzed.
In summary, our results showed that DM and PM pa-
tients have different characteristics from the point of view 
of muscle MRI, just like physiopathological and histological 
findings.
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